Gemoscan Canada Inc.

CNSX : GES


Gemoscan Canada Inc.

June 21, 2011 08:00 ET

Gemoscan Adds Personalized Vitamins & Supplements to the Hemocode Food Intolerance System, Forms Strategic Alliance With Pharmetics for Retail Distribution

TORONTO, ONTARIO--(Marketwire - June 21, 2011) -

Attention Food, Nutrition and Business Editors:

Gemoscan Canada Inc. (CNSX:GES) announced today that Canadians will soon have broader access to one of the world's most advanced systems for identifying and relieving food intolerances, and to personalized vitamin and supplement recommendations for those who suffer from food intolerances.

The Toronto-based company has added an individualized vitamin and supplement module to its Hemocode Food Intolerance System and formed a strategic alliance with Pharmetics Inc, a leading supplier of more than 1,300 varieties of vitamins, supplements and over-the-counter pharmaceuticals. Pharmetics services many of North America's leading food, drug and mass merchants.

The Gemoscan-Pharmetics alliance will provide Canadians with improved access to the Hemocode System at retailers across Canada, where Pharmetics' superior quality, retail-branded products are available, while enabling retailers to grow their emerging wellness business.

"Canadians are eager for information about diet and its effect on overall wellness – particularly when it's customized to their needs – and that's what makes Hemocode unique," says Brian Kalish, president and chief executive officer of Gemoscan. "Identifying personal food intolerances that affect nearly 30 per cent of Canadians and helping them balance their diets through individually recommended vitamins and supplements, is what our Hemocode System is all about. And now, thanks to our alliance with Pharmetics, it will be easier than ever for consumers to get a more complete diet-related wellness solution, in their own neighbourhoods."

By adding personalized vitamin and supplement recommendations, the Hemocode System will help consumers move towards optimal nutrition as they work to eliminate offending foods from their diets. No other food intolerance program offers this type of seamlessly delivered, highly customized solution. In addition to delivering a meaningful wellness benefit to their customers, the inclusion of dietary supplement recommendations as part of Hemocode creates an opportunity for retailers to recognize: accretive revenue from Hemocode System sales; incremental growth in their core vitamin program and an enhancement of their market differentiation.

"The strategic alliance with Gemoscan is a great fit for Pharmetics and offers our retail customers an incremental, value-added service to address consumers' ever-growing interest in diet and diet-related wellness," says Michael Ash, senior vice-president of sales and marketing at Pharmetics. "Working with Gemoscan also creates a natural opportunity to support and increase sales of our customers' core products."

The Hemocode System

The Hemocode System is a personalized nutritional program that includes a proprietary and patented, state-of-the-art blood analysis that identifies and delivers relief from the individually unique symptoms of immuno-based food intolerances. Each consumer receives highly personalized food elimination recommendations, and vitamin and supplement recommendations to provide greater wellness through relief from food intolerances.

This information is delivered by way of a report, personalized recipe books and access to medical professionals. Developed by a team of nutritionists and medical practitioners, the Hemocode System takes the guess work out of deciphering what variety of 250 common foods and additives can potentially offend and adversely affect personal lifestyle and wellness. Consumers begin with a simple finger-prick test that is sent for analysis using a patented system that includes assays and sophisticated algorithms. Within seven to ten business days, consumers receive their personal Hemocode System materials.

The Hemocode System is administered by and includes initial and on-going consultation with Naturopathic Doctors and other licensed medical professionals. The test is currently available at select Rexall Pharmacies and online at www.hemocode.com.

ABOUT GEMOSCAN

Founded in 2003 Gemoscan owns and markets the Hemocode System, a well-being assessment and treatment program that uses its own patented technology and services to detect and provide recommendations for the management of food intolerance and its often associated lifestyle affecting conditions such as fibromyalgia, chronic migraines and headaches, weight management, sleeplessness and others.

Gemoscan trades on the Canadian National Stock Exchange under the ticker GES and is quoted on the Munich Stock Exchange under the ticker 1GE.

Forward-Looking Information

This news release contains certain "forward-looking information". All statements, other than statements of historical fact, that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward-looking statements are subject to a number of significant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.

The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.

Contact Information